Por: Fox Business Business November 02, 2022
Check out what's clicking on FoxBusiness.com GSK opened 2% higher in U.S. trading Wednesday but closed down 2%. Shares rose after the drugmaker reported financial results that beat Wall Street forecasts and announced the Food and Drug Administration had accepted a biologics license application and granted priority review to its vaccine for respiratory syncytial virus (RSV) targeted at adults aged 60 years or older. The vaccine review marks... + full article
MarketWatch USA Business November 02, 2022
Operating profit was GBP1.19 billion, down slightly from GBP1.38 billion, due to the fair-value loss on the retained stake in consumer-healthcare business Haleon, which was spun off earlier in the year. Total earnings per share also fell to 18.8 pence from 21.9 pence for the... + más
GSK Raises 2022 Guidance as 3Q Sales Beat Expectations -- Update | MarketWatch
GSK 3Q Sales Expected Lower, But Possible Guidance Upgrade on the Horizon -- Earnings Preview | MarketWatch
Newsweek USA Health November 02, 2022
Pfizer announced positive trial results on Tuesday for a vaccine designed to help protect against the respiratory syncytial virus, or RSV, potentially setting up the company to have the first shot of its kind to be approved against the virus.The exact timeline for the vaccine... + más
Strong RSV vaccine data lifts hopes after years of futility | 10 WBNS
Pfizer says study shows vaccinating pregnant women protects newborns from RSV | ABC7
CNN USA Health October 19, 2022
CNN — The US Food and Drug Administration on Wednesday among adults 18 and older, at least six months after completing a primary Covid-19 vaccine series. The company announced that it has received emergency use authorization to provide a first booster dose of its vaccine... + más
FDA authorizes Novavax's Covid shots as mix-and-match booster to Pfizer or Moderna | CNBC
US clears Novavax COVID booster dose | ABC News
Forbes USA Tech October 13, 2022
On September 12, the European Commission authorized the use of the Nuvaxovid Covid-19 vaccine as ... [+] both a homologous and heterologous booster for adults 18 years of age and older. (Photo by Patrick van Katwijk/Getty Images)Getty Images The Barenaked Ladies may have sung,... + más
Omicron-specific vaccine boosters get FDA sign-off | The Verge
CDC recommends Covid omicron booster shots for kids as young as 5 years old | CNBC
RTTNews USA Health October 10, 2022
The FDA has approved GSK plc's () Boostrix vaccine for immunization during the third trimester of pregnancy to prevent pertussis, commonly known as whooping cough, in infants younger than two months of age. The agency noted that Boostrix (Tetanus Toxoid, Reduced Diphtheria... + más
FDA clears vaccine to prevent whooping cough in newborns by giving shot to mother during pregnancy | CNBC
FDA warns against 'very unsafe' social media trends targeted at teenagers | ABC News
ABC News USA Health September 30, 2022
WASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.Amylyx Pharmaceuticals said the Food and... + más
Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post
ALS drug wins FDA approval despite questionable data | WPLG Local 10
About iurex | Privacy Policy | Disclaimer |